Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX in Advanced Salivary Gland Cancers
NCT00101075Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2004
- Primary completion
- Mar 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in salivary gland cancer (SGC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Tumor response rate. Started Oct 2004; status: terminated.
02
Drugs
capecitabineoxaliplatin
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT00101075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00101075.